Elexacaftor
Elexacaftor is a medication that acts as cystic fibrosis transmembrane conductance regulator (CFTR) corrector.

It is available in a single pill with ivacaftor and tezacaftor; the fixed-dose combination, elexacaftor/tezacaftor/ivacaftor (brand name "Trikafta"), is used to treat people with cystic fibrosis who are homozygous for the f508del mutation. This combination was approved for medical use in the United States in 2019.

The fixed-dose combination elexacaftor/tezacaftor/ivacaftor (Kaftrio) was approved for medical use in the European Union in August 2020, for the treatment of cystic fibrosis.
Q420470
cystic fibrosis transmembrane conductance regulator
Concept
Q6095693
ivacaftor
Concept
Q27270940
tezacaftor
Concept
Q1779868
fixed-dose combination
Concept
Q72184040
elexacaftor/tezacaftor/ivacaftor
Concept
Q178194
cystic fibrosis
Concept
Q420470
f508del
Concept
Q72184089
Elexacaftor
Concept
2019-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
2019
DATE
2020-08-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
August 2020
DATE
+508^^http://www.w3.org/2001/XMLSchema#decimal
508
NUMBER
medical condition treated
part of
part of
instance of